Filing Details

Accession Number:
0001493152-22-028929
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-10-19 19:22:25
Reporting Period:
2022-10-18
Accepted Time:
2022-10-19 19:22:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1394319 Tracon Pharmaceuticals Inc. TCON Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1595855 Opaleye Management Inc. One Boston Place, 26Th Floor
Boston MA 02108
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Acquisiton 2022-10-18 10,000 $1.65 3,790,000 No 4 P Indirect By Opaleye, L.P.
Common Stock, Par Value $0.001 Per Share Acquisiton 2022-10-18 2,500 $1.65 4,125,000 No 4 P Indirect By Managed Account.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Opaleye, L.P.
No 4 P Indirect By Managed Account.
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Prefunded Warrants $0.01 2020-08-27 2030-08-27 1,889,513 1,889,513 Indirect
Common Stock Prefunded Warrants $0.01 2020-08-31 2030-08-31 1,358,593 1,358,593 Indirect
Common Stock Prefunded Warrants $0.01 2022-06-21 2032-06-21 2,205,018 2,205,018 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2030-08-27 1,889,513 1,889,513 Indirect
2030-08-31 1,358,593 1,358,593 Indirect
2032-06-21 2,205,018 2,205,018 Indirect
Footnotes
  1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
  2. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
  3. The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.